Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICT 01

Next Previous
Drug Profile

ICT 01

Alternative Names: ICT-01; ICT01 - ImCheck Therapeutics

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImCheck Therapeutics
  • Class Anti-infectives; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Butyrophilin inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Ovarian cancer; Squamous cell cancer; Urogenital cancer
  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Solid tumours
  • Research Infections

Most Recent Events

  • 22 May 2025 Efficacy and adverse events data from the phase I/II EVICTION trial in Haematological malignancies released by ImCheck Therapeutics
  • 25 Apr 2025 Adverse events, pharmacodynamics and efficacy data from a phase I/II EVICTION trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 20 Jan 2025 Phase-I clinical trials in Malignant melanoma (Combination therapy, Second-line therapy or greater) (IV) before January 2025 (ImCheck Therapeutics pipeline, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top